Patient Profile 1: A 51-Year-Old Man with High-Risk Localized Prostate Cancer

Data showed that all patients achieved a PSA decline of at least 50%.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

"Most of the published data about HIFU tended to be with relatively short-term follow-up," says Ralph J. Miller Jr, MD.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

Data from the CAPItello-281 trial also showed a trend toward an improvement in overall survival.

In the recent news release, Koelis reported that the final patient was enrolled in the VIOLETTE study in September 2024.